Revvity, Inc., announced today the launch of the in-vitro diagnostic EURORealTime™ APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy for Alzheimer’s disease.